For Veterans

Learn how veterans with ALS can get started with RADICAVA® (edaravone) through the Department of Veterans Affairs (VA).

Veteran Access to RADICAVA®

RADICAVA® is on the Veterans Affairs National Formulary (VANF)a

To be eligible for treatment with RADICAVA®, veterans must be cared for by a VA neurologist or VA-purchased-care neurologist.

brochure with information for veterans with ALS to access RADICAVA® (edaravone)

Information for Veterans with ALS


aSubject to National Prior Authorization criteria.

Getting patients started with treatment at the VA

If your patient is already in the VA healthcare system:

  • They need to see their primary care physician for a referral to their closest VA neurologist or VA-purchased-care neurologist
  • If they have a My HealtheVet Premium Account, they can make an appointment using the VA Appointments tool. Otherwise, they need to contact their local VA location to make their appointment

If your patient is not currently enrolled in the VA healthcare system, they may still qualify for ALS treatment through the VA. To get started they can apply:


Important Safety Information

Hypersensitivity Reactions

Radicava® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Radicava®. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported. Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue Radicava®, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions

Radicava® contains sodium bisulfite, and may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatic people.

Most Common Adverse Reactions

Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.


Based on animal data, Radicava® may cause fetal harm.

Geriatric Use

No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or


Radicava® is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Please see full Prescribing Information.

For more information about RADICAVA®, call 1-888-292-0058.